MedTech for the majority – Innovations for the next billion

The MedTech landscape in 2025 is evolving at the crossroads of innovation and inclusion. As technology advances rapidly, the industry focuses is on scalable, cost-effective solutions that serve broader populations.

Medical technology is revolutionizing healthcare and shaping how doctors diagnose, treat, and manage diseases. From life-saving surgical robots to AI-driven diagnostics, MedTech innovations are making healthcare more precise, efficient, and accessible. As the industry continues to evolve, healthcare software development and emerging technologies like wearable biosensors, smart implants, and personalized medicine pave the way for a future where medical treatments are tailored to individual needs.

Reflecting this momentum, the global MedTech size was valued at approximately USD 668.2 billion in 2024 and is projected to reach USD 694.7 billion by the end of 2025–a year-over-year growth of about 4 percent.

While a 4 percent growth rate may seem modest compared to other tech-driven industries, it reflects sustained investment, regulatory advancements, and increasing demand for digital health solutions. Given the rapid adoption of wearable devices, remote patient monitoring, and precision medicine, this steady rise suggests that MedTech is becoming an integral part of global healthcare systems. MedTech continues to evolve and become more visible in the public space, reshaping how healthcare is delivered and improving patient outcomes.

India – The next global MedTech powerhouse
India’s MedTech sector is experiencing a transformative evolution, positioning the country as a rising global leader. Once a nascent industry, India’s MedTech landscape is expanding rapidly, driven by strategic diversification, robust government initiatives, and a dynamic startup ecosystem. As the sector gains prominence, India is gradually shedding its heavy dependence on medical equipment imports–currently around 80–85 percent–by scaling local manufacturing efforts. With approximately 150 devices once imported, now produced domestically, India is poised to meet domestic needs while expanding its export potential. This shift is not only fostering self-reliance but is also setting the stage for India to emerge as a key player in the global MedTech market, projected to reach ₹4.25 lakh crore by 2030.

A significant driver behind this growth is the sector’s ability to innovate and adapt to local needs while keeping affordability at the forefront. The rise in digital health technologies, including AI-driven diagnostics, wearable devices, and mobile health applications, is revolutionizing the healthcare delivery model in India. These innovations, combined with growing urban demand, rising incomes, and expanding insurance coverage, fuel the sector’s expansion.

India’s large population, increasing digital adoption, and policy support offer a strong foundation for MedTech start-ups to innovate for both local impact and global reach. Today, over 10,000 MedTech start-ups–growing annually at 15–20 percent–are actively addressing healthcare challenges using AI, IoT, and cloud computing technologies. Many of these ventures have secured international regulatory approvals such as US FDA and CE marks, enabling them to enter global markets and strengthen India’s export outlook.

Additionally, government-backed initiatives such as the Production-Linked Incentive (PLI) schemes, financial support for medical device parks, and Foreign Direct Investment (FDI) encouragement strengthen India’s manufacturing capabilities, further bolstering the country’s competitiveness. Reforms like the Medical Device Rules (2017) and the National Medical Device Policy (2023) create a favourable regulatory landscape, encouraging manufacturing, research, and development across the sector.

Complementing this industrial growth is a series of public-private collaborations that aim to bridge the gap between start-ups, healthcare providers, and regulatory bodies. With programs focused on clinical validation, real-world evidence generation, and market access, India is cultivating an ecosystem that accelerates the adoption of cutting-edge MedTech innovations. This holistic approach–integrating policy reform, industry support, and start-up incubation–ensures that India can leverage its competitive advantages, including low labour costs and a skilled workforce, to drive domestic and international MedTech growth.

India’s MedTech ambitions extend beyond innovation and manufacturing. A growing focus on global market integration, particularly in the U.S. and European markets, is evident as Indian companies secure international regulatory approvals and scale their product portfolios. By leveraging its software, hardware, and cost-effective labour strengths, India is strategically tapping into the global China plus one supply chain model, diversifying the international medical device market. This shift not only positions India as a potential alternative supplier to global markets but also presents significant export opportunities, with projections estimating up to ₹1.7 lakh crore in exports by 2030.

Technological integration, particularly in robotics, AI, and digital health, shapes India’s MedTech future. Innovations like robotic surgery are improving the precision of minimally invasive procedures, and augmented reality is revolutionizing surgical training. While challenges such as infrastructure limitations and regulatory barriers remain, these technological advancements promise to significantly improve patient outcomes and accessibility, particularly in underserved regions.

While challenges such as infrastructure limitations, scalability, and regulatory complexities remain, the momentum in India’s MedTech journey is undeniable. With a vibrant startup base, forward-looking policies, and an eye on global expansion, India is not just transforming its healthcare landscape–it’s shaping the future of MedTech worldwide.

MedTech momentum – Domestic push, global ambitions, and sectoral shifts
India’s MedTech sector is witnessing a multifaceted evolution marked by strategic responses to global competition, shifting investor focus, and a more profound digital transformation. Amid rising concerns over the influx of low-cost Chinese medical devices, Indian industry associations have approached the government seeking safeguards to protect and promote indigenous manufacturers, aligning with the broader goal of reducing import dependency and boosting local innovation.

At the same time, while the government claims a drop in out-of-pocket expenditure (OOPE), the rising cost of surgeries, some reportedly reaching ₹300,000, points to the need for more transparent pricing and robust healthcare financing mechanisms. In parallel, private equity (PE) investors increasingly favor single-specialty hospitals, especially in Tier II and III cities, recognizing the potential for scalable, focused care models.

Indian MedTech manufacturers see a significant opportunity to replace China as a leading supplier of critical medical devices to global markets-particularly the US-by elevating their quality standards and strengthening regulatory compliance. This strategic shift is supported by robust advancements in precision manufacturing, adoption of international standards like ISO 13485, and alignment with global regulatory frameworks, positioning India as a credible and competitive alternative in the international medical device industry.

Tech for longevity
As the global population ages rapidly, the focus shifts from simply adding years to life to adding healthy, active years. MedTech stands at the forefront of this transformation and is pivotal in extending health spans through early diagnosis, continuous monitoring, and personalized treatment. From wearable sensors and implantable devices to advanced imaging and digital health platforms, medical technology enables proactive, preventive care, helping individuals manage chronic conditions more effectively and maintain independence longer. Innovations in minimally invasive surgery, remote monitoring, and AI-assisted diagnostics are reshaping the way we age, supporting a future where people live longer and better.

Middle East – Rising as a MedTech innovation hub
The Middle East is also rapidly emerging as a dynamic force in the global MedTech landscape, propelled by robust economic growth, ambitious government initiatives, and rising healthcare needs. With the global MedTech market projected to surpass USD 960 billion by 2030, the region–particularly Saudi Arabia, the UAE, and Qatar–is taking bold steps not only to keep pace but to lead.

These nations are making strategic investments in next-generation technologies, from AI and robotics to telemedicine and precision diagnostics. Saudi Arabia’s Vision 2030 and the UAE’s Mubadala Healthcare are pivotal in this transformation, laying the foundation for a self-sustaining MedTech ecosystem that emphasizes local innovation, manufacturing, and workforce development.

At the same time, shifting dynamics in global trade–particularly the U.S.’s recent tariff measures–are creating ripple effects that stretch well beyond North America. As the U.S. imposes baseline tariffs of 10 percent or more on imported components, and raises duties as high as 125 percent on Chinese goods, many MedTech manufacturers are rethinking their supply chains. The resulting uncertainty and rising production costs in the U.S. are prompting companies to explore alternative markets for sourcing, manufacturing, and investment.

This opens a window of opportunity for the Middle East. As global firms seek tariff-safe and innovation-friendly environments, the region’s increasingly attractive business climate–bolstered by free trade zones, investment incentives, and advanced infrastructure–positions it as a natural contender for MedTech investment and collaboration.

Traditionally dependent on imports, the Middle East is evolving into an innovation-driven hub. The surge in MedTech incubators, start-up accelerators, and strategic partnerships with global R&D institutions speaks to a new entrepreneurial era. Qatar, for example, is carving out a niche in genomics, gene therapy, and oncology diagnostics, with dedicated funding and research facilities reshaping its healthcare capabilities.

Digital transformation is at the heart of this momentum. AI-powered diagnostic platforms, cloud-based patient records, and integrated health data systems are transforming care delivery–making it more efficient, predictive, and personalized. The UAE and Saudi Arabia are rolling out robust digital health strategies, enabling remote monitoring, virtual consultations, and intelligent diagnostics. Dubai Healthcare City, with its pro-innovation regulations and growing venture capital ecosystem, is fast becoming a launchpad for regional and global MedTech innovators.

Nevertheless, challenges remain. Regulatory alignment across countries, data privacy frameworks, and skilled workforce shortages must be addressed to sustain growth. However, the trajectory is promising. As the U.S. tariffs inject volatility into traditional MedTech strongholds, the Middle East’s steady rise offers a compelling counterbalance–one that could capture a larger share of global attention, resources, and innovation.

In this new MedTech era, the Middle East is not merely reacting to global shifts–it is defining them.

Tariffs, tensions, and a turning point for US MedTech
The US government’s new tariff policy–notably a 125 percent levy on Chinese goods–has sent ripples through the medical device industry, triggering concern over rising costs, disrupted supply chains, and potential international retaliation. While large players may absorb short-term shocks, startups and mid-sized firms could face severe financial strain, especially in sectors heavily reliant on imported components like surgical instruments, wearables, and diagnostics.

However, these challenges also open up opportunities. Experts believe that the industry could pivot toward domestic manufacturing and supply chain diversification with the right policy incentives, such as tax breaks and R&D grants. A recent survey of global MedTech leaders underscores proactive strategies like reshoring, forming international alliances, strategic stockpiling, and policy advocacy as key to navigating the turbulent trade environment.

Though short-term uncertainty prevails, the long-term outlook could be optimistic if the MedTech industry adapts strategically and receives strong government support. The sector now stands at a crossroads, with a chance to reshape its global competitiveness.

Trends to watch in 2025
The MedTech sector is entering a transformative era, driven by robotics, biomaterials, and patient-centric care innovation. In 2025, key trends are reshaping healthcare delivery with precision and purpose.

AI and machine learning are transforming personalized medicine by analyzing complex data, enhancing surgical planning, and improving outcomes. From AI-driven 3D modeling to AR-assisted robotic surgeries, these technologies are ushering in a new era of precision and predictive care.

Minimally invasive technologies such as surgical interventions are evolving with advanced tools like AR guidance, microscale instruments, and robotic systems, enabling greater precision, faster recovery, and reduced trauma. Innovative single-access robotic platforms are redefining the future of minimally invasive surgery.

Biomaterial research for improved implants are rapidly evolving to enhance implant integration with human tissue, reduce immune reactions, and promote faster healing. Innovations in titanium alloys, ceramic materials, and surface modifications are paving the way for durable, biocompatible implants that offer improved long-term performance and patient outcomes.

Transcatheter valve technology, advances in transcatheter aortic valve technology, particularly Transcatheter Aortic Valve Replacement (TAVR), have revolutionized the treatment of aortic valve stenosis. TAVR offers a minimally invasive alternative to open-heart surgery, with innovations in valve design enhancing durability, hemodynamic performance, and ease of implantation. Initially developed for high-risk patients, TAVR is now expanding to benefit intermediate and low-risk individuals, improving patient outcomes and accessibility.

Heart valve technology has advanced significantly, improving treatments for valvular heart diseases. Both mechanical and tissue valves now replicate natural heart function more effectively. Mechanical valves, crafted from durable materials like titanium, offer enhanced longevity and optimized hemodynamics, while tissue valves, derived from animal tissues, benefit from anti-calcification treatments to extend their lifespan. Innovations in tissue-engineered technologies are further advancing heart valve solutions, ensuring safer, longer-lasting options and improved patient outcomes.

Bioresorbable implants such as bioresorbable stents (BRS) are transforming coronary artery disease (CAD) treatment by providing temporary support that gradually degrades and is absorbed by the body. These stents, designed with ultra-thin struts and advanced drug-eluting coatings, minimize complications associated with permanent implants while promoting faster healing. Future BRS innovations include personalized degradation timelines and multi-drug platforms targeting inflammation, thrombosis, and restenosis for enhanced patient outcomes.

Significant advancements
A significant innovation in MedTech is nanosecond pulsed field ablation (nsPFA), a cutting-edge treatment for atrial fibrillation (AFib) and other conditions. Unlike traditional techniques, nsPFA uses ultra-short electrical pulses to target abnormal tissue without damaging surrounding structures, offering a nonthermal alternative to heat or cold-based therapies.

This technology provides faster, deeper ablations with fewer side effects, such as muscle stimulation and nerve damage. With systems like CellFX nsPFA, Pulse Biosciences is advancing treatments for cardiac and non-cardiac conditions, including pulmonary vein ablation for AFib and benign thyroid nodule ablation.

The tunable nature of nsPFA allows for customized treatment, improving precision and patient outcomes. As clinical evidence grows, nsPFA is poised to transform medical treatments, providing a safer, more effective approach to managing complex health conditions.

Another, notable advancements in MedTech is the development of non-invasive treatments that provide patients with safer and more efficient options for managing chronic conditions. A prime example is MR-guided focused ultrasound (MRgFUS), which uses high-intensity ultrasound waves, guided by MRI, to target specific areas of the brain. This approach is particularly beneficial for conditions like Parkinson’s disease, offering an alternative to traditional surgical treatments without the associated risks.

MRgFUS avoids the need for invasive procedures like deep brain stimulation (DBS), providing a safer and less risky option with a quicker recovery time.

These non-invasive therapies are already showing promising results in improving patients’ quality of life, helping them regain independence and reduce their reliance on caregivers. This shift towards non-invasive options is revolutionizing the way chronic neurological conditions, such as Parkinson’s, are treated, offering more personalized, efficient, and safer care for patients.

In addition, one advancement in diabetes management comes from the groundbreaking use of 3D bioprinting technology. A research team from Pohang University of Science and Technology (POSTECH), led by Professor Jinah Jang, has developed an innovative platform for diabetes treatment using bioinks derived from pancreatic tissue. This development holds the potential to transform how diabetes is treated by offering therapies that are more effective.

The POSTECH team created PINE bioink, containing laminin and collagen IV, to replicate the extracellular matrix (ECM) and vascular structures of the pancreas. Using 3D bioprinting, they developed the HICA-V platform, which arranges stem cell-derived islet cells and vascular structures, closely mimicking a functional pancreas.

The HICA-V platform enhances insulin production, supports islet maturation, and simulates diabetic conditions, making it a valuable tool for research and drug development. This innovation has the potential to improve islet transplantation therapies and accelerate the development of more effective anti-diabetic treatments.

Backed by funding from South Korean institutions, this technology represents a significant step forward in personalized medicine and diabetes care. As 3D bioprinting continues to evolve, it could revolutionize regenerative medicine, offering patient-specific solutions and transforming the future of diabetes management.

Driving sustainability in MedTech
Sustainability in MedTech is no longer an optional add-on–it is becoming a core design and manufacturing philosophy. Eco-conscious manufacturing and product design are at the heart of this transformation, reshaping how medical devices are developed, used, and disposed of. By integrating environmental responsibility into every stage of the product lifecycle, MedTech companies are not only reducing their ecological footprint but also future proofing their operations in a world increasingly defined by climate awareness and regulatory oversight.

At the product design level, sustainability begins with thoughtful material selection. Designers are moving away from conventional plastics and non-renewable resources in favour of recyclable, biodegradable, or bio-based alternatives that reduce pollution and support a circular economy. Minimizing the number of components, reducing material volume, and designing for disassembly are all key elements of sustainable product architecture. These principles allow for easier recycling, refurbishment, and repair–thereby extending product life and reducing waste.

In manufacturing, eco-conscious strategies focus on energy efficiency, waste minimization, and cleaner production methods. Closed-loop systems, where waste is recycled back into production, are becoming increasingly common. Companies are also investing in renewable energy, smart manufacturing technologies, and passive environmental controls in production facilities to cut down carbon emissions without compromising quality or sterility.

Eco-conscious practices in MedTech also respond to a new era of regulation and consumer expectations. Emerging policies like the EU’s Ecodesign Regulation and the UK’s post-Brexit sustainability framework demand transparency in material sourcing, lifecycle environmental impact, and end-of-life product management.

Ultimately, sustainable manufacturing and design not only protect the planet but also offer measurable business advantages. Reduced waste, lower energy costs, and fewer regulatory risks translate into operational efficiency and improved margins.

At the same time, brands that lead on sustainability are better positioned to attract eco-conscious investors, gain customer trust, and secure a competitive edge in a crowded marketplace. Through eco-conscious manufacturing and design, the MedTech industry can continue to deliver life-saving innovations while safeguarding the health of both people and the planet.

Balancing innovation with sustainability is both a challenge and an opportunity for MedTech landscape. As the industry pushes the boundaries of design and functionality, it must also confront growing environmental concerns and regulatory demands. Forward-thinking companies are now embedding sustainability into the earliest stages of product development–carefully considering materials, lifecycle impacts, packaging, and disposal methods.

However, this balance is not always easy to achieve. High costs and limited access to eco-friendly materials often complicate efforts, while lifecycle assessments are frequently overlooked in the rush to innovate. Still, by adopting circular economy principles, conducting end-to-end environmental evaluations, and investing in next-gen sustainable technologies, MedTech manufacturers can create solutions that are both cutting-edge and responsible.

In addition, sustainability in MedTech is no longer driven solely by regulations–it’s being shaped from both the ground up and the top down. Grassroots initiatives, often led by healthcare professionals, researchers, and local communities, are pushing for greener practices, such as minimizing single-use plastics and promoting responsible disposal of medical waste.

At the same time, industry leaders are launching bold sustainability programs that prioritize eco-friendly product design, energy-efficient manufacturing, and transparent supply chains. Together, these grassroots movements and corporate commitments are creating a powerful momentum toward a more sustainable MedTech ecosystem.

Strategic visions for reimagining sustainable MedTech
As healthcare contributes, approximately 4.4 percent of global carbon emissions–70 percent of which stem from supply chains–the MedTech industry faces growing pressure to rethink its approach. The rapid rise of connected home healthcare only adds to the complexity, shifting waste management responsibilities to patients. This calls for a strategic reimagining of how MedTech devices are designed, used, and disposed of.

A sustainable MedTech future begins with designing for sustainability. This means integrating eco-conscious thinking from the outset–choosing recyclable materials, creating modular systems for easier disassembly, and reducing packaging waste.

Innovation must also extend to patient-centric waste solutions. As more care shifts to the home, manufacturers must ease the burden on users by offering intuitive take-back programs, biodegradable materials, and clearer disposal guidance. Achieving this vision requires systemic collaboration across the ecosystem–bringing together manufacturers, healthcare professionals, regulators, and payers to incentivize sustainable innovation without compromising care quality.

Learning from practical benchmarks, such as sustainability data from leading continuous glucose monitors (CGMs), can offer a valuable blueprint for reducing the carbon footprint of connected medical devices. Ultimately, reimagining MedTech is about balancing environmental stewardship with clinical performance–paving the way for a greener, smarter, and more resilient healthcare future.

Unlocking the power of IP
Unlocking intellectual property (IP) is crucial for enabling affordable MedTech solutions to reach global markets. As innovative start-ups and small-to-medium enterprises (SMEs) continue to develop breakthrough medical technologies, IP plays a pivotal role in protecting their innovations and ensuring long-term success. By securing patents, trademarks, and data rights, these companies safeguard their inventions, enabling them to secure funding, form strategic partnerships, and navigate complex regulatory environments. A well-structured IP strategy not only protects their creations but also provides opportunities for licensing, collaboration, and market expansion, all of which contribute to making MedTech solutions more accessible to underserved populations worldwide.

In addition to providing protection, IP can unlock new revenue streams that drive affordability in MedTech. By leveraging IP portfolios strategically, companies can attract investment, secure non-dilutive funding, and collaborate with larger players in the healthcare ecosystem, facilitating broader distribution of their innovations. These collaborations help address pricing challenges by making cutting-edge technologies more scalable, while ensuring that products are tailored to local regulatory requirements and health needs. Ultimately, a robust IP strategy enables MedTech companies to scale their solutions globally, reducing costs and increasing access to critical healthcare innovations in remote and low-resource settings.

Bridging gaps in continuum of care
The role of MedTech in integrated, patient-centric healthcare is becoming increasingly vital as healthcare systems evolve to meet the demands of modern patient care. As the focus shifts from merely diagnosing conditions to providing continuous, comprehensive care, MedTech plays a crucial role in bridging the gaps within the continuum of care.

From the moment a patient is diagnosed to post-treatment recovery, MedTech solutions are facilitating smoother transitions between different stages of care. This integration ensures patient data flows seamlessly across various healthcare touchpoints, enabling healthcare providers to deliver personalized, real-time, and informed care.

MedTech innovations, particularly in wearable devices and diagnostic tools, enable patients to manage their health in a proactive and preventive manner. Devices that monitor vital signs, track glucose levels, or assess heart health, empower patients to take control of their wellness, leading to better outcomes. By incorporating real-time data from such devices into electronic health records (EHRs), healthcare providers are equipped with a more holistic view of the patient’s condition, making it easier to detect early signs of complications and adjust treatment plans promptly. This patient-centric approach, facilitated by MedTech, not only improves immediate care but also contributes to long-term health outcomes by supporting patients in managing chronic conditions, reducing hospital readmissions, and promoting healthier lifestyles.

As the healthcare landscape continues to prioritize continuity and quality of care, the role of MedTech in integrating services and enhancing patient care will only continue to grow, shaping the future of healthcare delivery.

AI’s growing role in MedTech
AI is rapidly advancing the MedTech sector, transforming everything from diagnostics to surgery. In recent years, AI has moved past the hype stage and is now firmly integrated into medical devices, revolutionizing patient care, and improving efficiency. In 2024, AI-driven medical devices, such as the Symani Surgical System, have received FDA approval, reflecting the increasing confidence in AI’s ability to enhance healthcare outcomes. This robotic platform, which uses AI to perform precision microsurgeries, exemplifies how AI models can achieve accuracy far beyond human limits. Similarly, AI is making its mark through smaller applications, such as decision-support tools for clinicians and health-monitoring apps, which help doctors, make faster, more informed decisions.

In diagnostics, AI-powered devices, particularly in imaging, significantly improve accuracy by processing medical data to identify anomalies that human eyes might miss. This advancement, combined with predictive analytics, enables proactive healthcare, where AI can identify health risks early, allowing for timely interventions. This shift from reactive to preventive care is also facilitated by wearable devices, which collect real-time health data and alert users to potential health issues before they escalate. AI’s real-time monitoring of health trends empowers patients to take control of their conditions, leading to better long-term outcomes.

Beyond diagnostics, AI is enhancing the surgical landscape. Real-time surgical navigation, driven by advanced computational imaging, provides surgeons crucial updates during procedures, reducing risks and improving precision. Intraoperative AI tools enable adjustments mid-operation, ensuring more accurate outcomes, especially in complex surgeries. Integrating AI-driven surgical guidance systems enhances efficiency, providing continuous support throughout procedures. Furthermore, tissue visualization technologies, powered by AI, allow surgeons to navigate complex anatomical structures with unprecedented precision, transforming traditional imaging methods.

AI’s potential is not limited to surgery and diagnostics; it is poised to reshape healthcare delivery entirely. As consumer demographics evolve, with millennials, Gen X, and Gen Z becoming the primary healthcare consumers, there is a growing demand for personalized, on-demand services. Biometric data will be increasingly integrated into daily life, with AI streamlining diagnostics and preventive care. The convergence of technologies, such as wearable devices and AI-powered home diagnostics, will make healthcare more efficient while reducing the need for specialized medical equipment. The future of healthcare may see the repurposing of outdated infrastructures, such as gas stations, into neighbourhood health stations, making healthcare more accessible and decentralized.

Integrating AI into MedTech is about improving patient care and creating a more personalized, efficient, and accessible healthcare experience. AI promises to play a central role in reducing the burden on healthcare professionals, automating routine tasks, and providing continuous monitoring of patients, even after they leave the hospital. With AI-driven advancements, healthcare will shift towards a model that is invisible, omnipresent, and seamlessly integrated into daily life, where healthcare becomes not a location or building but a continuous experience aimed at enhancing human flourishing.

Roadblocks for MedTech
The global MedTech industry, while thriving with innovation and consistent growth, faces a complex web of roadblocks that must be navigated carefully to sustain momentum and drive future success. Cross-border collaboration, often essential for product development and market access, introduces a set of cultural and operational challenges. Differences in language, work styles, and business norms can create friction in communication and workflow, especially when smaller firms partner with larger corporations and risk losing quality control oversight. These cultural nuances, if unaddressed, can hinder productivity and collaboration outcomes.

Compounding these interpersonal and organizational challenges are the intricate and often fragmented regulatory landscapes across regions. Each country maintains its approval protocols and compliance requirements, such as the FDA in the United States, CE marking in the European Union, and now India’s evolving regulatory framework under the National Medical Devices Policy 2023. As companies strive to innovate, they must also invest heavily in navigating these diverse systems. In India, steps like joining the International Medical Device Regulators Forum (IMDRF) and proposals for harmonized product classifications aim to reduce uncertainty, especially for startups and smaller players who often lack the resources to endure prolonged approval timelines.

Alongside these regulatory demands lies the critical issue of intellectual property protection. In transnational collaborations, discrepancies in IP laws across countries can complicate the safeguarding of innovations. Clear agreements and legal frameworks must be in place to ensure ownership and usage rights are respected throughout the development cycle.

Another pressing concern for MedTech companies is profit margin pressure driven by rising input and operational costs. As highlighted in one of the industry report, spending on commercial models–particularly selling, general, and administrative (SG&A) expenses–continues to grow rapidly, eroding profitability. Simultaneously, shifting reimbursement models and financial constraints within healthcare systems delay approvals and reduce incentives for new product adoption, especially for high-risk or high-cost technologies.

The industry’s financing environment has also tightened, with deal volumes in mergers and acquisitions (M&A) hitting a 15-year low in 2023. Although deal value saw modest growth, the reduced activity reflects broader investor caution and economic uncertainty. Furthermore, innovation capital–once boosted by the urgency of the Covid-19 pandemic–has declined, with R&D funding shrinking significantly. This contraction in innovation spending jeopardizes the pipeline of next-generation technologies, including those based on AI and robotics.

Despite its potential, integrating digital technologies introduces new vulnerabilities, particularly in cybersecurity. As medical devices become increasingly connected, the sector is grappling with a surge in cyberattacks, including ransomware threats that can disrupt or manipulate critical healthcare systems. Regulatory frameworks like the EU MDR and IVDR have imposed stricter cybersecurity requirements, including secure development life cycles and IT safeguards. Further regulations, such as the upcoming EU Cyber Resilience Act, will soon extend to non-medical digital components, making proactive compliance necessary for market access and a strategy for risk mitigation and competitiveness.

Talent shortages and supply chain constraints further amplify the challenges in India. While government schemes like the Human Resource Development and Capacity Building programs offer some relief, there remains a scarcity of skilled professionals in R&D and a lack of local component suppliers, making it difficult for domestic manufacturers to scale affordably. Meanwhile, balancing safety with speed to market remains a delicate task for regulators, as both patient safety and timely product access must be maintained.

Additionally, the growing complexity of reimbursement systems and pricing caps for medical devices in India exerts downward pressure on profitability, particularly for high-end and imported technologies.

A path forward
MedTech is stepping up with transformative solutions as the global demand for cost-effective healthcare rises, driven by aging populations, chronic diseases, and the push for equity. In 2025, bold investments, strategic acquisitions, and cross-sector collaboration are fuelling a new wave of innovation. Start-ups and industry leaders focus on scalable technologies that address real-world needs, ensuring healthcare is not just advanced, but accessible and affordable. MedTech for the majority is no longer a distant vision–it’s a growing reality, reshaping medicine for the next billion and beyond.

Industry Speaks

Medical ventilator market in India – Trends and technologies.

The changing landscape of the ICU vital monitoring.

About the Glasgow ECG interpretation algorithm.

The versatile evolution of C-arm imaging systems  in modern healthcare.

India’s MedTech industry – From import reliance to global competitiveness.

The quintessential need to innovate and add value to India’s medical device industry.

Shaping the future with smarter medical devices.